Core Viewpoint - Eli Lilly's latest research results on Tirzepatide for the treatment of obesity combined with psoriasis show potential for skin symptom clearance and weight loss, possibly expanding new indications [1] Stock Performance - Eli Lilly's stock experienced significant volatility over the past week, with a notable single-day increase of 4.86% due to negative news from competitors, followed by a pullback, resulting in a cumulative fluctuation of 0.89% [1] - The latest closing price for Eli Lilly is $1029.60, with an active trading volume reaching $1.988 billion in a single day [1] Institutional Insights - Analysis from Hexun indicates that Eli Lilly is leveraging strategies such as expanding indications, AI pharmaceutical collaborations, and launching new formulations to comprehensively suppress Novo Nordisk, demonstrating its generational advantages in technology and commercialization [1]
礼来替尔泊肽减肥药研究获进展 股价单日大涨4.86%
Xin Lang Cai Jing·2026-02-25 22:29